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We describe the case of a 75-year-old woman who presented with massive tongue and lip swelling secondary to angiotensin-
converting enzyme inhibitor-induced angioedema. An awake fibre-optic intubation was performed because of impending airway
obstruction. As there was no improvement in symptoms after 72 hours, the selective bradykinin B2 receptor antagonist icatibant
(Firazyr) was administered and the patient’s trachea was successfully extubated 36 hours later. To our knowledge this is the first
documented case of icatibant being used for the treatment of angiotensin-converting enzyme inhibitor-induced angioedema in the
United Kingdom and represents a novel therapeutic option in its management.
1. Introduction
Angiotensin-converting enzyme inhibitor- (ACEi-) induced
angioedema is one form of bradykinin-mediated angioe-
dema. It occurs in less than 1% of patients receiving treatment
with ACEi. The effect is not dose-related and is a class effect.
It may occur at any time after beginning treatment with the
drug, with 60% of patients developing symptoms within the
first week [1]. The tongue, lips, and eyes are predominantly
affected with stridor or respiratory failure occurring in 11% of
cases [2].
Icatibant, a highly selective bradykinin B2 receptor antag-
onist, is used in the treatment of acute attacks of hereditary
angioedema [3]. However, several case reports have docu-
mented that it can be used safely and successfully for the
treatment of ACEi-induced angioedema. We describe what
we believe to be the first reported case in the UK of ACEi-
induced angioedema treated successfully with icatibant.
2. Case Report
A 75-year-old hypertensive, diabetic, Afro-Caribbean lady
presented to the emergency department with a two-hour
history of progressive tongue swelling. On arrival she was
unable to speak or swallow secretions but had no evidence
of stridor. She had profound tongue and lip swelling con-
sistent with angioedema. On further examination, there
was no evidence of rash or wheeze. She had no known
allergies.
Ramipril (2.5mg OD) had been prescribed 3 days earlier
by her general practitioner in addition to her other regular
medication, atenolol, amlodipine, bendroflumethiazide, and
metformin. She had so far taken two 2.5mg tablets of
ramipril, the last one on the preceding evening.
Initial observations showed an arterial oxygen saturation
of 99% on room air with no evidence of cardiovascular com-
promise. Immediate management involved delivery of high
flow oxygen, intramuscular adrenaline 0.5mg, intravenous
hydrocortisone 200mg, and intravenous chlorphenamine
10mg. Despite these measures the tongue swelling continued
and, in view of the onset of stridor, the patient was transferred
to theatre for an awake fibre-optic intubation. This was
performed with an ENT surgeon on stand-by and proved
extremely difficult due to severe distortion of the upper
airway anatomy.
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Figure 1: Before and after treatment with icatibant.
The patient was subsequently transferred to the Intensive
Care Unit (ICU) for supportive management. After 72 hours
there had been no resolution of symptoms despite regular
administration of dexamethasone and chlorphenamine.After
discussion with the immunology team it was felt appropriate
to consider the off-license use of icatibant (Shire Human
Genetic Therapies Inc.) for this patient, as the risks of
continued intubation and ventilationwere considered greater
than the use of icatibant.
Icatibant is administered as a 30mg subcutaneous injec-
tion into the anterior abdominal wall, up to a maximum dose
of 90mg within 24 hours. The first dose was administered on
ICU day four and a significant reduction in tongue swelling
was noticed within 30 minutes (Figure 1). Two further doses
were administered 8 hours apart by which time the tongue
swelling had almost completely resolved.
Despite resolution of angioedema within the first few
hours of icatibant administration, weaning from mechan-
ical ventilation was delayed as the patient had developed
a ventilator-associated pneumonia. Successful extubation
eventually took place 36 hours after the first dose of icatibant.
No adverse effects were noted apart from mild erythema
around the injection site. The patient was discharged to the
ward on day six (Figure 2), where she required a period of
rehabilitation, after which she was discharged home. She was
advised to avoid ACEi in the future.
3. Discussion
Angiotensin-converting enzyme inhibitors (ACEi) are one
of the most commonly prescribed antihypertensive drugs
and are a well-known, but often unrecognised, cause of
angioedema. The incidence of ACEi-induced angioedema is
between 0.1%–0.7% which may progress to airway compro-
mise [1, 4].
ACEi block the conversion of angiotensin-I to
angiotensin-II, lowering arteriolar resistance and increasing
venous capacitance, and thereby exerting an antihypertensive
effect. ACEi also inhibit the breakdown of bradykinin into
its fragmentation products leading to an accumulation of
circulating bradykinin. It is this accumulation which leads to
one of the commonest side-effects of ACEi, the dry cough. In
some patients however, the accumulation of bradykinin also
Figure 2: After extubation.
leads to increased vascular permeability, interstitial oedema,
and finally angioedema (Figure 3).
This is very similar to the pathophysiology of heredi-
tary angioedema which is mediated mainly by bradykinin-
induced activation of vascular bradykinin B2 receptors
[4]. This explains why traditional therapies for ”allergic”
angioedema (e.g., food allergy) are ineffective, as none act
directly or indirectly on the bradykinin pathways responsible
for the angioedema [4, 5].
Icatibant is a synthetic decapeptide which competitively
inhibits bradykinin B2 receptors on the vascular endothe-
lium. It displaces endogenous bradykinin and leads to
reversal of angioedema by reducing vascular endothelial
permeability.
Icatibant was licensed in 2008 for use in hereditary
angioedema [6, 7]. A phase III randomised controlled trial
comparing icatibant to placebo or tranexamic acid demon-
strated a significant reduction in time to subjective and
objective resolution of symptoms in the icatibant group
[3]. Interest in icatibant for the treatment of ACEi-induced
angioedema is growing with a recent case series showing
significant symptom reduction within a mean time of 50.6
minutes [4]. In this case series none of the patients required
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Figure 3: Mechanism of ACEi-induced angioedema.
tracheal intubation or tracheostomy tube insertion and no
serious adverse events were reported.
Icatibant has a high bioavailability (97%) and maximal
concentration in the serum is achieved in around 30 minutes
[7]. A single dose of the drug has been shown to be effective
in the majority of cases [8]. However, the terminal plasma
half-life of icatibant is 1-2 hours and hence more than one
dose may be necessary. Local reactions (pain, erythema,
and swelling) are common side-effects and the drug is not
recommended in individuals with acute cardiac or brain
ischaemia [6, 7].
Due to the acute presentation of ACEi-induced
angioedema and its low incidence, the use of icatibant in this
situation has previously been off-license and confined to case
reports and case series. However, a phase III, randomized,
controlled trial evaluating the safety and efficacy of icatibant
as a treatment for ACEi-induced angioedema in adults is
currently ongoing and we await the results of this trial with
interest [9].
4. Conclusion
The increasing prevalence of ACEi use indicates that the
frequency of related cases of angioedema will also increase.
The use of icatibant is well-recognised among the immunol-
ogy community, but knowledge of its benefits is extremely
limited in the acute care setting. Increasing awareness of this
drug’s existence as a potential alternative to intubation and
ventilation may lead physicians to consider it as a treatment
option early in the course of the disease.
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